PD-L1 testing across tumor indications · INDICATION PD-L1 testing across tumor indications...
Transcript of PD-L1 testing across tumor indications · INDICATION PD-L1 testing across tumor indications...
INDICATION
PD-L1 testing across tumor indications
TREATMENT ALGORITHM CLONES CUT-OFF
References: 1. Dolled-Filhart M., et al. Development of a companion diagnostic for pembrolizumab in non–small cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch Pathol Lab Med. 2016;140(11):1243–1249.2. Reck M., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer. N Engl J Med. 2016; 375(19):1823-1833.3. Antonia S.J., et al. Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018; 379:2342-2350.4. Herbst R.S., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. 5. Balar A.V., et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;
18(11):1483–1492.6. Balar A.V., et.al. Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicenter, phase 2 trial. Lancet 2017;389(10064):67-76.7. Burtness B., et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomized, open-label phase 3
study. Lancet. 2019; 394(10212):1915-1928.8. Schmid P., et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018; 379(22):2108-2121.
Abbreviations: TPS: Tumor Proportion Score; CPS: Combined Positive Score; Cis-ineligible UC: cisplatin-ineligible urothelial cancer; LDT: Laboratory Developed Test; IC: Immune cells; 5-FU: 5-fluorouracil
≥ 50%
≥ 1%
CPS• 22C3 PharmDx kit• 22C3 LDT
≥ 10
≥ 5%Ventana PD-L1 (SP142) Assay
Non-small cell lung cancer
2L
Urothelial Carcinoma
IC
Responsible editor: Belgian Society of Pathology
Date of last revision: 12/2019
• 22C3 PharmDx kit• 22C3 LDT• Ventana PD-L1
(SP263) Assay
Please consult the prescribing information before prescribing, via www.fagg.be
≥ 1%IC
Triple-Negative Breast Cancer
1LAtezolizumab + nab-paclitaxel8
Head and Neck Squamous Cell
Carcinoma
≥ 1*CPS1LPembrolizumab7
with or without platinum+5-FU
• 22C3 PharmDx kit• 22C3 LDT
*To be reported as CPS<1, CPS≥1 or CPS≥20
TPS
Pembrolizumab1,2
Pembrolizumab4
Durvalumab3
DISEASE STAGE
≥ 1%
Metastatic
Locally advanced,
unresectable
Locally advanced or metastatic
1L
Atezolizumab6
1LLocally
advanced or metastatic
Cisplatin-ineligible
Ventana PD-L1 (SP142) Assay
Metastatic or unresectable
recurrent
Metastatic
Responsible editor: Belgian Society of Pathology
Pembrolizumab5